HBG1 and sickle cell disease: Moreover, we mapped de novo L1-ORFeus insertions in cells undergoing ABE8e editing at two disease-relevant loci (BCL11A enhancer and HBG1/2 promoter) currently being evaluated for gene therapy of sickle cell disease and β-thalassemia72–74 (Supplementary Fig. 13c, m, n).